Alx Oncology Holdings Inc (ALXO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Alx Oncology reported revenue of $0. Net income was -$101.7M, or -$1.90 per diluted share. Operating activities generated -$84.1M of cash, leaving -$84.4M of free cash flow. At fiscal year end, Alx Oncology held $59.0M in total assets against $33.1M in total liabilities, including $16.4M of cash and equivalents.
Open the full interactive Alx Oncology financials → Quarterly statements, key ratios, valuation history and price charts.
Alx Oncology Key Stats
| Share Price | $0.98 |
|---|---|
| Market Cap | $132.9M |
| 52-Week Range | $0.98 – $2.60 |
| Shares Outstanding | 135.6 million (basic, 2026 Q2) |
Alx Oncology Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$43.7M | -$83.6M | -$127.4M | -$170.3M | -$142.5M | -$104.0M |
| Pre-Tax Income | -$45.5M | -$83.5M | -$123.4M | -$160.8M | -$134.8M | -$101.7M |
| Income Tax | $241,000 | -$21,000 | $64,000 | — | — | $0 |
| Net Income | -$45.7M | -$83.5M | -$123.5M | -$160.8M | -$134.8M | -$101.7M |
| Diluted EPS | -$2.76 | -$2.07 | -$3.03 | -$3.74 | -$2.58 | -$1.90 |
Alx Oncology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$22.1M | -$22.8M | -$17.9M | -$18.0M |
| Diluted EPS | -$0.41 | -$0.43 | -$0.17 | -$0.13 |
Alx Oncology Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $434.2M | $363.7M | $48.8M | $22.4M | $17.6M | $16.4M |
| Current Assets | $436.0M | $367.0M | $271.0M | $188.7M | $134.4M | $50.7M |
| Total Assets | $436.1M | $380.2M | $306.5M | $242.6M | $147.8M | $59.0M |
| Current Liabilities | $6.2M | $15.3M | $28.3M | $36.0M | $18.5M | $24.6M |
| Total Long-Term Debt | — | — | $10.6M | $10.6M | $9.9M | $9.7M |
| Total Liabilities | $6.2M | $17.1M | $43.0M | $52.8M | $34.2M | $33.1M |
| Shareholders' Equity | $429.8M | $363.0M | $263.5M | $189.7M | $113.6M | $26.0M |
Alx Oncology Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$38.3M | -$68.1M | -$89.2M | -$130.4M | -$121.9M | -$84.1M |
| Cash From Investing | $610,000 | -$4.9M | -$235.4M | $44.7M | $86.3M | $82.6M |
| Cash From Financing | $462.9M | $2.5M | $9.9M | $59.3M | $30.8M | $362,000 |
| Free Cash Flow | -$38.3M | -$68.8M | -$90.7M | -$131.6M | -$122.4M | -$84.4M |
Figures from Alx Oncology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Alx Oncology financials page for every line item.
Alx Oncology Company Profile
| Ticker | ALXO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001810182 |
Frequently Asked Questions
What was Alx Oncology's revenue in fiscal 2025?
Alx Oncology (ALXO) reported revenue of $0 for fiscal 2025.
What is Alx Oncology's annual revenue history?
Alx Oncology's annual revenue by fiscal year: 2020: $1.2M; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Alx Oncology's net income in fiscal 2025?
Alx Oncology reported net income of -$101.7M for fiscal 2025.
What was Alx Oncology's earnings per share (EPS) in fiscal 2025?
Alx Oncology's diluted EPS was -$1.90 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Alx Oncology generate in fiscal 2025?
Alx Oncology generated -$84.4M of free cash flow in fiscal 2025.
What was Alx Oncology's revenue last quarter?
In its most recent reported quarter (2026 Q2), Alx Oncology reported revenue of $0.
How much debt does Alx Oncology have?
Alx Oncology reported $9.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Alx Oncology are outstanding?
Alx Oncology reported a weighted average of 135.6 million basic shares outstanding in 2026 Q2.
What is Alx Oncology's market cap?
Based on its latest closing price, Alx Oncology (ALXO) has a market capitalization of about $132.9M.
When does Alx Oncology's fiscal year end?
Alx Oncology's fiscal year end, as registered with the SEC, is December 31.
Where is Alx Oncology headquartered?
Alx Oncology lists its business address in South San Francisco, California in its SEC filings.